Abstract
Carboxypeptidase A (CPA) is one of the most extensively studied zinc proteases and serves as a prototypical enzyme for a large family of metalloproteases that play important roles in biological systems. CPA has been used as a model enzyme for developing design strategies of inhibitors that restrain the catalytic activity of zinc proteases. Recently, there has been made a remarkable progress in designing small molecule inactivators that inhibit the enzymic activity of CPA irreversibly by chemically modifying a functional group at the active site of the enzyme. Of these irreversible inhibitors mechanism-based inactivators are of special interest due to their high selectivity for target enzyme and long duration of enzyme inhibition. These inactivators have been designed rationally on the basis of established topology of the active site and catalytic mechanism of the enzyme. Chemistry inherent to the zinc ion at the active site of the enzyme has been exploited in the design. The present review covers the progress in the CPA inactivator design strategy. The design strategy developed with CPA may be transferred to other zinc proteases of medicinal interest, leading to discovery of a novel type of therapeutically useful enzyme inhibitors.
Keywords: Carboxypeptidase, proteases, zinc, enzyme inhibition
Current Topics in Medicinal Chemistry
Title: Chemistry-based Design of Inhibitors for Carboxypeptidase A
Volume: 4 Issue: 12
Author(s): Dong H. Kim
Affiliation:
Keywords: Carboxypeptidase, proteases, zinc, enzyme inhibition
Abstract: Carboxypeptidase A (CPA) is one of the most extensively studied zinc proteases and serves as a prototypical enzyme for a large family of metalloproteases that play important roles in biological systems. CPA has been used as a model enzyme for developing design strategies of inhibitors that restrain the catalytic activity of zinc proteases. Recently, there has been made a remarkable progress in designing small molecule inactivators that inhibit the enzymic activity of CPA irreversibly by chemically modifying a functional group at the active site of the enzyme. Of these irreversible inhibitors mechanism-based inactivators are of special interest due to their high selectivity for target enzyme and long duration of enzyme inhibition. These inactivators have been designed rationally on the basis of established topology of the active site and catalytic mechanism of the enzyme. Chemistry inherent to the zinc ion at the active site of the enzyme has been exploited in the design. The present review covers the progress in the CPA inactivator design strategy. The design strategy developed with CPA may be transferred to other zinc proteases of medicinal interest, leading to discovery of a novel type of therapeutically useful enzyme inhibitors.
Export Options
About this article
Cite this article as:
Kim H. Dong, Chemistry-based Design of Inhibitors for Carboxypeptidase A, Current Topics in Medicinal Chemistry 2004; 4 (12) . https://dx.doi.org/10.2174/1568026043387908
DOI https://dx.doi.org/10.2174/1568026043387908 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Traditional Chinese Medicine in Treatment of Metabolic Syndrome
Endocrine, Metabolic & Immune Disorders - Drug Targets Effects of Maternal Obesity on Maternal and Fetal Health
Current Women`s Health Reviews Stiff Left Atrial Syndrome; Prospects and Possibilities. Retrospective Analysis and Review of the Literature
Current Hypertension Reviews Genetic Polymorphisms in the Growth Hormone Receptor: Impact on Growth Response and Disease Susceptibility
Current Pharmacogenomics and Personalized Medicine Hypoxia-Inducible Factor-1 in Arterial Disease: A Putative Therapeutic Target
Current Vascular Pharmacology Mitochondrial Dysfunction, Oxidative Stress and Diabetic Cardiovascular Disorders
Cardiovascular & Hematological Disorders-Drug Targets Benign Prostatic Hyperplasia and Clinical Prostate Cancer - Two New Components of the Metabolic Syndrome
Current Hypertension Reviews A Brief Review of Blue- and Bilberries’ Potential to Curb Cardio-Metabolic Perturbations: Focus on Diabetes
Current Pharmaceutical Design Physical and Mental Functions of Cardiovascular Diseased Patients Decrease During the State of Emergency Initiated by the COVID-19 Pandemic in Japan
Reviews on Recent Clinical Trials Cardiovascular Disease in Patients with Diabetic Nephropathy
Current Molecular Medicine Endothelin-1 Actions on Vascular Smooth Muscle Cell Functions As a Target for the Prevention of Atherosclerosis
Current Vascular Pharmacology Immune Thrombocytopenic Purpura: New Biological Therapy of an Old Disease
Current Medicinal Chemistry Recent Advance in Isoform-Specific Regulation of Adenylyl Cyclase
Current Enzyme Inhibition Atypical Presentation Of Anti-Retroviral Therapy Induced Lactic Acidosis as Acute Right Ventricular Failure And Severe Pulmonary Hypertension
New Emirates Medical Journal Safety and Efficacy of Duloxetine in the Treatment of Diabetic Peripheral Neuropathic Pain in Older Patients
Current Drug Safety Gene Patents in the Primary Prevention of Vascular Diseases
Recent Patents on DNA & Gene Sequences Current Status of Hormone Replacement Therapy in Post Menopausal Women
Current Drug Therapy Novel Biomarkers Assessing Renal Function in Heart Failure: Relation to Inflammatory Status and Cardiac Remodelling
Current Medicinal Chemistry Vitamins in Heart Failure: Friend or Enemy?
Current Pharmaceutical Design Therapeutic Implications of Tocilizumab, A Humanized Anti-Interleukin-6 Receptor Antibody, for Various Immune-Mediated Diseases: An Update Review
Current Rheumatology Reviews